Article Figures & Data
Figures
- Fig. 1.
Vertical scatter plots demonstrating absolute gene expression levels in individual tumors and benign glands from the initial microarray profiles. In all cases, the lower expression threshold is 70.8, representing the scaled noise of the noisiest GeneChip in the experiment. Scaled average difference values less than the threshold were adjusted to 70.8 and, therefore, overlap. A, genes that vary in tumors relative to normal glands. B, expression levels of Cdk10, serotonin receptor 2B, and Pgm-5 plotted with a reduced Y axis to better demonstrate their ranges of expression. C, genes that vary in metastases relative to primary tumors. Symbols correspond to specific pathological descriptions: A and B, •, tumor; ▴, benign. C, •, metastasis; ▴, primary tumor. Horizontal bars average gene expression in each respective sample set.
- Fig. 2.
Vertical scatter plots demonstrating relative expression levels for hepsin and Pgm-5 in an independent set of malignant and nonmalignant samples. By quantitative RT-PCR, these two genes both exhibited significant (P < 0.01 and P < 0.05, respectively) expression differences between malignant and nonmalignant samples in the validation sample set. Horizontal bars, average expression of hepsin and Pgm-5 in malignant and nonmalignant sample sets.
- Fig. 3.
In situ hybridization for hepsin expression in the prostate. H&E stains of an adjacent frozen section are shown at right. A and B, a low-power view of a prostate specimen with both benign (arrows) and malignant (arrowheads) epithelia. Hepsin is specifically overexpressed in malignant glands. C and D, a high-power view of malignant prostate epithelia overexpressing hepsin. E and F, a high-power view of PIN lesions that also overexpress hepsin. G and H, a high-power view of benign epithelia within the cancer specimen. Note that the benign glands to not express hepsin at appreciable levels.
Tables
- Table 1
Misregulated genes in benign and malignant prostate samples
Accession Mean avg difference Mean avg difference Mean fold difference P Genea cdk 10 L33264 71 ± 0b 950 ± 519c 13.4 <0.001 Hepsin X07732 186 ± 230b 7915 ± 4939c 42.5 <0.001 Serotonin receptor 2B X77307 71 ± 0b 322 ± 161c 4.5 <0.001 Gened Phosphoglucomutase 5 L40933 1136 ± 373b 109 ± 83c 10.4 0.011 Descriptione HMG-CoA reductase M11058 80 ± 27f 335 ± 73g 4.2 0.021 Rad50 U63139 82 ± 24f 333 ± 36g 4.1 0.003 Geneh TYRO3 protein tyrosine kinase U18934 952 ± 301f 134 ± 57g 7.1 <0.001 Diacylglycerol kinase X62535 1294 ± 527f 127 ± 97g 10.2 <0.001 Pyridoxal kinase U89606 628 ± 487f 71 ± 0g 8.8 0.014 Stabilin 1/KIAA0246 D87433 1240 ± 506f 98 ± 24g 12.6 <0.001 Protein kinase C, β 1 X07109 1125 ± 541f 80 ± 16g 14.1 <0.001 Butyrophilin U90552 390 ± 196f 71 ± 0g 5.5 0.002 Early growth response 3 X63741 596 ± 374f 71 ± 0g 8.0 0.005 Early growth response 2 J04076 881 ± 615f 101 ± 12g 8.7 0.009 G protein α 16 M63904 913 ± 752f 71 ± 0g 12.9 0.016 -
a Up-regulated in tumors relative to normal.
-
b Normal.
-
c Tumor.
-
d Down-regulated in tumors relative to normal.
-
e Up-regulated in metastases relative to primaries.
-
f Primaries.
-
g Mets.
-
h Down-regulated in metastases relative to primaries.
-
Volume 61, Issue 15
